Semaglutide · research summary

Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease.

Medicine · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Retrospective observational study
“This retrospective observational study included 126 patients with T2DM complicated by CKD who were treated at our hospital between March 2023 and July 2024.”

Subjects

Patients with Type 2 diabetes mellitus complicated by chronic kidney disease
“This retrospective observational study included 126 patients with T2DM complicated by CKD who were treated at our hospital between March 2023 and July 2024.”

Sample size

126 patients (42 in each of 3 treatment groups)
“The final analytic cohort comprised 42 patients in each group; the equal group size reflected the eligible records with complete baseline and 8-week follow-up data available in each treatment category during the study period rather than a prospective 1:1:1 enrollment target.”

Duration

8 weeks
“The treatment duration was 8 weeks.”

Reported findings

All three treatment groups showed significant reductions in glycemic indices, renal function parameters, and inflammatory markers compared to baseline.
“After 8 weeks of treatment, fasting plasma glucose, 2-hour postprandial plasma glucose, hemoglobin A1c, blood urea nitrogen, serum creatinine, 24-hour urinary protein, erythrocyte sedimentation rate, interleukin-6, and high-sensitivity C-reactive protein were significantly reduced in all 3 groups compared with baseline.”
The combination therapy group demonstrated greater short-term reductions in measured parameters and a higher clinical response rate than monotherapy groups.
“The combination group showed greater short-term reductions in glycemic indices, renal function-related parameters, and inflammatory markers than either monotherapy group.”
No statistically significant increase in recorded adverse events was detected between groups during the observation period.
“No statistically significant between-group differences were detected in the recorded incidence of hypoglycemia, nausea and vomiting, rash, abdominal distension or diarrhea, headache or dizziness, or urinary tract infection during the 8-week observation period.”

Limitations stated by the authors

Retrospective design, modest sample size, short observation period, single center, and lack of longitudinal eGFR assessment.
“Because of the retrospective design, modest sample size, and short observation period, these findings should not be interpreted as demonstrating definitive long-term renal benefit or equivalent long-term safety.”

Source: PubMed 42854065 · DOI 10.1097/MD.0000000000051019 · all study summaries

Sample size

126 patients (42 in each of 3 treatment groups)

“The final analytic cohort comprised 42 patients in each group; the equal group size reflected the eligible records with complete baseline and 8-week follow-up data available in each treatment category during the study period rather than a prospective 1:1:1 enrollment target.”

Reported findings

All three treatment groups showed significant reductions in glycemic indices, renal function parameters, and inflammatory markers compared to baseline.

“After 8 weeks of treatment, fasting plasma glucose, 2-hour postprandial plasma glucose, hemoglobin A1c, blood urea nitrogen, serum creatinine, 24-hour urinary protein, erythrocyte sedimentation rate, interleukin-6, and high-sensitivity C-reactive protein were significantly reduced in all 3 groups compared with baseline.”

The combination therapy group demonstrated greater short-term reductions in measured parameters and a higher clinical response rate than monotherapy groups.

“The combination group showed greater short-term reductions in glycemic indices, renal function-related parameters, and inflammatory markers than either monotherapy group.”

No statistically significant increase in recorded adverse events was detected between groups during the observation period.

“No statistically significant between-group differences were detected in the recorded incidence of hypoglycemia, nausea and vomiting, rash, abdominal distension or diarrhea, headache or dizziness, or urinary tract infection during the 8-week observation period.”

Limitations stated by the authors

Retrospective design, modest sample size, short observation period, single center, and lack of longitudinal eGFR assessment.

“Because of the retrospective design, modest sample size, and short observation period, these findings should not be interpreted as demonstrating definitive long-term renal benefit or equivalent long-term safety.”